Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: Placebo; Drug: BIRT 2584 XX

• Registration Number: NCT02259894
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

To assess safety, tolerability, pharmacokinetics, and pharmacodynamics of BIRT 2584 XX in single rising oral doses of 5 mg to 700 mg in a polyethylene glycol 400 (PEG 400) solution in healthy subjects

Detailed Description

Not available

Study Timeline

• Study Start: 2004-03
• Primary Completion: 2004-06
• Status Verified: 2014-10
• Study First Submitted: 2014-10-07
• Study First Submitted QC: 2014-10-07
• Last Update Submitted: 2014-10-07
• Study First Posted: 2014-10-09
• Last Update Posted: 2014-10-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 55

Inclusion Criteria

• Healthy male subjects as determined by results of screening
• Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
• Age >=18 and <=50 years
• BMI >=18.5 and <=29.9 kg/m2

Read More

Exclusion Criteria

• Any finding of the medical examination (including blood pressure, pulse rate, and electrocardiogram) deviating from normal and of clinical relevance
• Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, haematological, oncological or hormonal disorders
• Surgery of gastrointestinal tract (except appendectomy)
• Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
• Relevant history of orthostatic hypotension, fainting spells or blackouts
• Chronic or relevant acute infections
• History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
• Intake of drugs with a long half-life (> 24 hours) (< 1 month prior to administration or during the trial)
• Use of any drugs, which might influence the results of the trial, (< 10 days prior to study drug administration or expected during the trial)
• Participation in another trial with an investigational drug (< 2 months prior to administration or expected during trial)
• Smoker (> 10 cigarettes or >3 cigars or >3 pipes/day)
• Alcohol abuse (> 60 g/day)
• Drug abuse
• Blood donation or loss > 400 mL, < 1 month prior to administration or expected during the trial
• Clinically relevant laboratory abnormalities
• Any ECG value outside of the reference range and of clinical relevance including, but not limited to QRS interval > 110 ms or QT interval, Bazett correction (QTcB) > 450 ms or QT interval >500 ms
• Inability to comply with dietary regimen of study centre
• Inability to comply with investigator's instructions

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	-
BIRT 2584	BIRT 2584 XX	single rising doses

Primary Outcome Measures

Name	Time	Method
Number of participants with adverse events	Up to 16 days after drug administration
Number of participants with clinically significant changes in vital signs	Up to 16 days after drug administration
Number of participants with abnormal changes in clinical laboratory parameters	Up to 16 days after drug administration
Number of participants with abnormal findings in 12-lead ECG (electrocardiogram)	Up to 16 days after drug administration
Number of participants with abnormal findings in physical examination	Screening and up to 16 days after drug administration

Secondary Outcome Measures

Name	Time	Method
Cmax (maximum concentration in plasma)	Up to 360 hours after drug administration
tmax (time from dosing to maximum concentration)	Up to 360 hours after drug administration
AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time) interval from 0 extrapolated to infinity)	Up to 360 hours after drug administration
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time) interval from 0 to the last quantifiable analyte plasma concentration)	Up to 360 hours after drug administration
λz (terminal rate constant in plasma)	Up to 360 hours after drug administration
t1/2 (terminal half-life of the analyte in plasma)	Up to 360 hours after drug administration
MRT(mean residence time of the analyte in the body)	Up to 360 hours after drug administration
CL/F (apparent oral clearance in plasma after oral administration)	Up to 360 hours after drug administration
Vz/F (apparent volume of distribution during the terminal phase λz) dose)	Up to 360 hours after drug administration
Ae0-48 (amount of analyte that is eliminated in urine from 0-48 hours)	Up to 48 hours after drug administration
fe0-48 (fraction of analyte eliminated in urine from 0-48 hours)	Up to 48 hours after drug administration
CLR,0-48 (renal clearance of the analyte from 0-48 hours)	Up to 48 hours after drug administration
Receptor occupancy as determined by binding of anti-LFA-1 antibody fragment (Fab)	Up to 360 hours after drug administration
Inhibition of IL-2 production	Up to 360 hours after drug administration	in response to superantigen challenge ex vivo